Recce Pharmaceuticals Ltd
RCE.ASXHealth Care
Pharmaceutical research and development.
Market Data
$0.550
-0.0%$159.1M
-100000.0x
$-0.114
0.00%
+0.1%
Latest Earnings
Appendix 4D and Interim Financial Report
27 February 2026
Recce Pharmaceuticals reported a H1 2025 loss of $16.6M (down 114% year-on-year), driven by increased R&D and share-based payment costs as the company advances its lead candidate RECCE®327 through Phase 3 clinical trials for diabetic foot infections in Indonesia. Key operational milestones include statistically significant efficacy data against MRSA and Pseudomonas aeruginosa, an A$85M Advanced Overseas Finding for R&D, and positive preclinical data for hospital-acquired pneumonia, though the company faces material going concern uncertainty with only $365k cash on hand and significant debt obligations. Key points: Phase 3 clinical trial for diabetic foot infections (DFI) now patient dosing underway with five sites activated in Indonesia; interim analysis built into protocol with Expedited Regulatory Review status; Statistically significant positive efficacy data demonstrating RECCE®327 activity against MRSA and Pseudomonas aeruginosa with substantial bacterial load reductions by Day 4–8 in burn wound rat models; A$85 million Advanced Overseas Finding approved for synthetic antibiotic R&D expenditure by Department of Industry, Science and Resources, providing future funding support
Recent Announcements
Appendix 4D and Interim Financial Report
Recce Pharmaceuticals reported a H1 2025 loss of $16.6M (down 114% year-on-year), driven by increased R&D and share-based payment costs as the company advances its lead candidate RECCE®327 through Phase 3 clinical trials for diabetic foot infections in Indonesia. Key operational milestones include statistically significant efficacy data against MRSA and Pseudomonas aeruginosa, an A$85M Advanced Overseas Finding for R&D, and positive preclinical data for hospital-acquired pneumonia, though the company faces material going concern uncertainty with only $365k cash on hand and significant debt obligations. Key points: Phase 3 clinical trial for diabetic foot infections (DFI) now patient dosing underway with five sites activated in Indonesia; interim analysis built into protocol with Expedited Regulatory Review status; Statistically significant positive efficacy data demonstrating RECCE®327 activity against MRSA and Pseudomonas aeruginosa with substantial bacterial load reductions by Day 4–8 in burn wound rat models; A$85 million Advanced Overseas Finding approved for synthetic antibiotic R&D expenditure by Department of Industry, Science and Resources, providing future funding support
Get real-time alerts for RCE
Receive AI-powered earnings summaries and instant notifications when Recce Pharmaceuticals Ltd releases results.
Register Free